BioMarin Pharmaceutical Maintains Strong Buy Rating with $98 Price Target

Oppenheimer analyst Leland Gershell reiterates a Buy rating on BioMarin Pharmaceutical with a price target of $98.00. The company's shares opened at $58.65. The analyst consensus is Strong Buy with a price target consensus of $98.82, representing a 68.49% upside. BioMarin reported Q2 revenue of $825.41 million and net profit of $240.53 million, compared to last year's revenue of $708.66 million and net profit of $107.17 million.

Oppenheimer analyst Leland Gershell reiterated his Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) on July 2, 2025, with a price target of $98.00. The company's shares opened at $58.65. The analyst consensus is Strong Buy with a price target consensus of $98.82, representing a 68.49% upside. BioMarin reported Q2 revenue of $825.41 million and net profit of $240.53 million, compared to last year's revenue of $708.66 million and net profit of $107.17 million.

The latest quarterly results showed significant growth in both revenue and earnings. Revenue increased by 16% year-over-year (YoY) and 17% at constant currency, while net profit grew by 124% YoY. These figures highlight BioMarin's strong performance and the potential for continued growth.

Gershell's rating and price target are in line with recent analyst sentiment, with several analysts maintaining a positive outlook on the stock. For instance, William Pickering of Bernstein Research also assigned a Buy rating with a price target of $95.00 [1]. Additionally, Barclays reaffirmed its Buy outlook, citing BioMarin's promising pipeline and strong growth prospects [2].

Despite the positive analyst sentiment, BioMarin's stock price has not fully reflected its strong fundamentals. The stock has been down 35% year-over-year, although momentum has improved somewhat in the past month. Analysts believe that the current price may represent an attractive entry point, given the company's robust earnings growth and promising pipeline.

However, it is essential to consider the potential risks associated with BioMarin's investment. Ongoing R&D costs and intensifying competition could dampen margins and growth if the company's new therapies face delays or market hurdles. Additionally, the valuation of the stock is a topic of debate among investors, with some suggesting that the stock may be undervalued, while others argue that it may be overvalued.

In conclusion, Oppenheimer's reiteration of a Buy rating on BioMarin Pharmaceutical Inc. is supported by the company's strong Q2 results and positive analyst sentiment. However, investors should carefully consider the potential risks and the valuation of the stock before making investment decisions.

References:
[1] https://finance.yahoo.com/news/bernstein-maintains-buy-rating-biomarin-152922629.html
[2] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/biomarin-pharmaceutical-bmrn-evaluating-valuation-following